Stentriever devices for removing an occlusive clot from a vessel and methods thereof

Information

  • Patent Grant
  • 11517340
  • Patent Number
    11,517,340
  • Date Filed
    Tuesday, December 3, 2019
    4 years ago
  • Date Issued
    Tuesday, December 6, 2022
    a year ago
  • Inventors
  • Original Assignees
  • Examiners
    • Holwerda; Kathleen S
    • Rwego; Kankindi
    Agents
    • Troutman Pepper Hamilton Sanders LLP
Abstract
Devices described herein include a stentriever for removing an occlusive clot. The stentriever can include a membrane cover on the proximal end which can be sized to form a seal with the tip of an intermediate catheter. Clot engagement sections and/or a distal engagement section of the stentriever can also include a full or partial membrane covering to control the direction of aspiration and/or areas where the aspiration applies suction to the thrombus or clot. The membranes can be used to direct the aspiration so as to pull the clot deeper into the clot engagement sections of the stentriever, thereby improving grip on the clot. The design can also increase the effectiveness of clot fragment protection for friable clots by providing pores and/or clot cells in a distal engagement section.
Description
FIELD OF INVENTION

The present disclosure generally relates to devices intended for removing acute blockages from blood vessels, and more particularly, to stentriever devices with membranes to direct fluid aspiration and enhance the stentriever's grip on an occlusive clot.


BACKGROUND

There are significant challenges associated with designing clot removal devices that can deliver high levels of performance. One challenge stems from the nature of the vasculature around an occlusive clot, which is often fragile and delicate. Neurovascular vessels, for example, are more fragile than similarly sized vessels in other parts of the body. Applying excessive tensile forces to these vessels could result in perforations and hemorrhage. Another challenge stems from the wide range of morphologies and consistencies of occlusive clots. Long strands of softer clot material may tend to lodge at bifurcations or trifurcations, resulting in multiple vessels being simultaneously occluded over significant lengths. More mature and organized clot material is likely to be less compressible than softer, fresher clot material, and under the action of blood pressure it may distend the compliant vessel in which the clot is lodged.


Stent-like clot retrievers, otherwise known as stentrievers, are being increasingly used to remove clots, as the devices show promise in dealing with some of the challenges described above. Stentrievers are self-expanding devices, similar in appearance to a stent attached to the end of a long shaft, which are advanced through a microcatheter and deployed across clot obstructions in order to trap and retrieve the clot. Many stentrievers rely on a pinning mechanisms to grab the clot by trapping the clot between the self-expanding, stent-like body and the vessel wall. Current stentrievers have a number of disadvantages that decrease the utility of the devices.


One disadvantage is that many stentrievers rely exclusively on an outward radial force (RF) to retain a grip on the clot. If the RF is too low the stentriever may lose its grip on the clot, but if the RF is too high the stentriever may damage the vessel wall and/or may require excessive force to withdraw the stentriever from the vessel. Stentrievers that apply sufficient RF to deal with all clot types may cause vessel trauma and serious patient injury, and stentrievers that apply low RF to remain atraumatic may not effectively handle all clot types.


Another disadvantage with current stentrievers is with the pinning mechanism itself. Stentrievers that rely exclusively on pinning clots against a vessel wall may not restrain the clot effectively when passing a branch vessel or when passing into a vessel that is larger than the fully expanded diameter of the stentriever. These and other disadvantages exist with previous stentriever devices. Accordingly, there is an ongoing need for an improved stentriever device that can improve grip on an occlusive clop without increasing the outward RF on the clot, thereby protecting the surrounding vasculature.


SUMMARY

Examples presented herein include stentrievers with membranes to direct fluid aspiration and enhance the stentriever's grip on an occlusive clot. The stentriever design described herein can include a membrane cover on the proximal end which can be sized to form a seal with the tip of an intermediate catheter. Clot engagement sections and/or a distal engagement section of the stentriever can also include a full or partial membrane covering to control the direction of aspiration and/or areas where the aspiration applies suction to the thrombus or clot. The membranes can be used to direct the aspiration so as to pull the clot deeper into the clot engagement sections of the stentriever, thereby improving grip on the clot. The design can also increase the effectiveness of clot fragment protection for friable clots by providing pores and/or clot cells in a distal engagement section.


An example stentriever can include a shaft extending between a proximal end and a distal end. A first expandable clot engagement section can extend from the shaft. The stentriever can include a proximal flow channel that is positioned proximal to the first expandable clot engagement section. The proximal flow channel can include a membrane covering to direct an aspiration from the first expandable clot engagement section and through the proximal flow channel. The stentriever can comprise a collapsed configuration to be inserted into a microcatheter and include an expanded configuration for exerting an outward radial force on an occlusive clot.


The first expandable clot engagement section can include a first clot inlet to capture the clot. The first clot inlet can be positioned on the stentriever distal to the first expandable clot engagement section.


The proximal flow channel can include a collapsed configuration to be inserted into a microcatheter, and the proximal flow channel can include an expanded configuration to exert an outward radial force on an intermediate catheter. In the expanded configuration, the proximal flow membrane can engage with an inner surface of the intermediate catheter at a proximal seal area do direct aspiration flow.


The first expandable clot engagement section can include a first clot engagement membrane directing the aspiration into the first expandable clot engagement section.


The stentriever can include a second expandable clot engagement section that extends from the shaft. The second expandable clot engagement section can be positioned distal to the first expandable clot engagement section.


The second expandable clot engagement section can include a second clot engagement membrane to direct the aspiration into the second expandable clot engagement section.


The second expandable clot engagement section can include a second clot inlet to capture the clot. The second clot inlet can be positioned on the stentriever distal to the second expandable clot engagement section.


The stentriever can include an intermediate flow channel positioned proximal to and adjacent the second expandable clot engagement section. The intermediate flow channel can direct the aspiration from the second expandable clot engagement section to the first expandable clot engagement section.


The stentriever can include a distal engagement section positioned distal to the first expandable clot engagement section. The distal engagement section can extend from the shaft. The distal engagement section can include a plurality of distal clot cells to capture clot fragments, such that the clot fragments do not pass distal to the stentriever.


The distal engagement section can include a distal membrane. The distal membrane can include distal pores that can constrict the flow of aspiration into the distal engagement section. The constriction of aspirate flow through the distal engagement section can create a negative pressure around the first and/or second expandable clot engagement sections to further pull the clot into the engagement sections.


The first expandable clot engagement section can further include a first clot inlet capturing the clot. A distal membrane can constrict flow from the distal engagement section to the proximal flow channel to create a negative pressure at the first expandable clot engagement section, thereby pulling the clot into the first clot inlet.


An example system for removing a clot from a vessel can include a stentriever. The stentriever can include a shaft extending between a proximal end and a distal end. The stentriever can include a first expandable clot engagement section extending from the shaft. The stentriever can include a proximal flow channel positioned proximal to and adjacent the first expandable clot engagement section. The proximal flow channel can include a proximal flow membrane. The system can further include an intermediate catheter. The stentriever can have a collapsed configuration to be inserted into a microcatheter, and the stentriever can have an expanded configuration to expand in a vessel. In the expanded configuration, the proximal flow cannel can exert a radial force on the intermediate catheter, and the proximal flow membrane can seal against the inner surface of the intermediate catheter. The aspiration can be directed from the first expandable clot engagement section, through the proximal flow channel, and into the intermediate catheter.


The first expandable clot engagement section can include a first clot inlet to capture a clot within the vessel.


The first expandable clot engagement section can include a first clot engagement membrane. The first clot engagement membrane can direct an aspiration into the first expandable clot engagement section.


The stentriever can further include a second expandable clot engagement section extending from the shaft. The second expandable clot engagement section can be positioned distal to the first expandable clot engagement section. The second expandable clot engagement section can further include a second clot inlet for capturing the clot.


The stentriever can further include an intermediate flow channel positioned proximal to and adjacent the second expandable clot engagement section. The intermediate flow channel can direct the aspiration from the second expandable clot engagement section to the first expandable clot engagement section.


The second expandable clot engagement section can include a second clot engagement membrane directing the aspiration into the second expandable clot engagement section.


The stentriever can include a distal engagement section positioned distal to the first expandable clot engagement section and extending from the shaft.


The distal engagement section can include a plurality of distal clot cells for capturing clot fragments.


The distal engagement section can include a distal membrane. The distal membrane can include distal pores that constrict flow of the aspiration into the distal engagement section. The constriction of aspirate flow through the distal engagement section can create a negative pressure around the first and/or section expandable clot engagement sections to further pull the clot into the engagement sections.


The distal membrane can include distal flow aperture directing the aspiration into the distal engagement section. The distal flow aperture can be a partial opening in the distal engagement section that constricts a flow of the aspirate into the distal engagement section. The constriction of aspirate flow through the distal engagement section can create a negative pressure around the first and/or section expandable clot engagement sections to further pull the clot into the engagement sections.


An example method for removing a clot from a vessel can include delivering a stentriever into the vessel and across the clot. The stentriever can include a shaft extending between a proximal end and a distal end. The stentriever can include an expandable clot engagement section extending from the shaft. The expandable clot engagement section can include a clot engagement membrane for directing a fluid into the expandable clot engagement section and a clot inlet. The stentriever can include a proximal flow channel positioned proximal to and adjacent the expandable clot engagement section. The proximal flow channel can include a proximal flow membrane. The proximal flow membrane can direct the fluid from the expandable clot engagement section and to the proximal flow channel. The method can include expanding the stentriever so that the expandable clot engagement section expands and exerts a radial force on the clot to engage the clot. The method can include advancing an intermediate catheter into the vessel and to the proximal flow channel. The proximal flow membrane can seal to an inner surface of the intermediate catheter. The method can include applying aspiration to the intermediate catheter such that a flow of the fluid is directed by the clot engagement membrane and into the proximal flow channel to capture the clot in the clot inlet. The method can include pulling the stentriever proximally to remove the clot from the vessel.


The stentriever can include a distal engagement section positioned distal to the expandable clot engagement section and extending from the shaft. The distal engagement section can include a distal membrane with a plurality of distal pores. The method can further include constricting, via the distal membrane, the flow of the fluid through the plurality of distal pores and into the distal engagement section. The constriction of the fluid flow can create a negative pressure to pull the clot into the clot inlet.


The distal engagement section can include a plurality of distal clot cells. The method can include preventing, via the plurality of distal clot cells, at least some clot fragments from passing distal to the stentriever.





BRIEF DESCRIPTION OF THE DRAWINGS

The above and further aspects of this invention are further discussed with reference to the following description in conjunction with the accompanying drawings, in which like numerals indicate like structural elements and features in various figures. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating principles of the invention. The figures depict one or more implementations of the inventive devices, by way of example only, not by way of limitation.



FIG. 1 is a side-view illustration of an exemplary stentriever, according to aspects of the present invention;



FIG. 2 is a side-view illustration of an exemplary stentriever interacting with an intermediate catheter, according to aspects of the present invention;



FIG. 3 is a side-view illustration of an exemplary stentriever having an intermediate flow channel, according to aspects of the present invention;



FIG. 4 is a top-view illustration of an exemplary stentriever, according to aspects of the present invention;



FIG. 5A is a side-view illustration of an exemplary stentriever having an inner channel, according to aspects of the present invention;



FIG. 5B is a side-view illustration of an exemplary inner channel, according to aspects of the present invention;



FIG. 6 is a perspective-view illustration of an exemplary stentriever with a full-length inner channel, according to aspects of the present invention;



FIG. 7A is a side-view illustration of an exemplary frame for a stentriever, according to aspects of the present invention;



FIG. 7B is a top-view illustration of the exemplary frame for a stentriever depicted in FIG. 7A, according to aspects of the present invention;



FIG. 8 is an end view of a partially-open distal engagement section, according to aspects of the present invention;



FIGS. 9A-91 depict an exemplary method of deploying a stentriever and removing an occlusive clot from a vessel, according to aspects of the present invention; FIG. 9A depicts a clot occluding a vessel; FIG. 9B a depicts a guide wire fed through the vessel and across the clot 10; FIG. 9C depicts a stentriever advanced through the microcatheter distal to the clot;



FIG. 9D depicts the microcatheter retracted proximally while the position of the stentriever is maintained; FIG. 9E depicts an intermediate catheter advanced to a proximal flow channel of the stentriever; FIG. 9F depicts aspiration being applied to the proximal flow channel via the intermediate catheter; FIG. 9G depicts a flow of the aspirate into the stentriever; FIG. 9H depicts the stentriever partially retracted into the intermediate catheter; and FIG. 9I depicts the stentriever retracted into the intermediate;



FIG. 10A is a flowchart depicting a method of removing a clot from a vessel, according to aspects of the present invention;



FIG. 10B is a flowchart depicting a method of using a distal engagement section to constrict flow and prevent clot fragments from passing distal to the stentriever, according to aspects of the present invention;



FIG. 11 is a flowchart depicting a method of deploying a stentriever, according to aspects of the present invention;



FIG. 12A is a flowchart depicting a method of removing a clot from a patient, according to aspects of the present invention; and



FIG. 12B is a flowchart depicting a method of removing a clot from a patient, according to aspects of the present invention.





DETAILED DESCRIPTION

Aspects of the present invention relate to a stentriever that includes a full or partial membrane cover on the proximal end of the device that is sized so that the proximal section can form a seal with the tip of an intermediate catheter. The stentriever device can include one or more expandable clot engagement sections and/or a distal engagement section. The expandable clot engagement sections and the distal engagement section can also include a membrane covering to control the direction of aspirate, and thus the direction of suction upon a thrombus or clot. The direction of aspirate can act to pull a clot deeper into inlet windows (i.e., clot inlets) of the expandable clot engagement sections. The direction of aspirate and suction can improve clot grip, decrease dislodgement of a clot within the stentriever, and increase retention of the clot when the clot is pulled into the intermediate catheter, access or guide catheter, or access sheath. In some examples, the design can also increase the effectiveness of clot-fragment protection for friable clots by providing antegrade flow through the distal engagement section.


Turning to the figures, FIG. 1 is a side-view illustration of an exemplary stentriever 100, according to aspects of the present invention. In some examples, this expanded configuration is exemplary of a stentriever 100 that is deployed into vessel. In some examples, a stentriever 100 can include a first expandable clot engagement section 102. The first expandable clot engagement section 102 can be an expandable feature that has a collapsed configuration and an expanded configuration, the expanded configuration being shown in FIG. 1. In a collapsed configuration, the first expandable clot engagement section 102 can be inserted into a microcatheter for deployment into a vessel and across a clot. It is contemplated that a diameter 103 of a first expandable clot engagement section 102 can be less than approximately 1.75 mm when the first expandable clot engagement section 102 is in a collapsed configuration. For example, ordinary microcatheters can have inner diameters of from 0.015 inches to 0.065 inches (approximately 0.38 mm to approximately 1.65 mm), and it is contemplated that a diameter 103 of a first expandable clot engagement section 102 can fall within these typical ranges. In the expanded configuration, the first expandable clot engagement section 102 can open to engage a clot within vessel by exerting a radial force upon the clot. A first expandable clot engagement section 102 can be manufactured according to the size of the vasculature in which the stentriever 100 is being deployed. It is contemplated that the diameter 103 of the expanded first expandable clot engagement section 102 can range from approximately 1.5 mm to approximately 7.0 mm, for example, and not limitation, approximately 4.00 mm. As used herein, the terms “about” or “approximately” for any numerical values or ranges indicate a suitable dimensional tolerance that allows the part or collection of components to function for its intended purpose as described herein. More specifically, “about” or “approximately” may refer to the range of values ±20% of the recited value, e.g. “about 90%” may refer to the range of values from 71% to 99%.


The first expandable clot engagement section 102 can be made from a material capable of recovering its shape automatically once unsheathed into its expanded configuration. The material could be in many forms such as wire, strip, sheet, or tube. In some examples, the first expandable clot engagement section 102 can include, but is not limited to, Nitinol, stainless steel, MP35N, tungsten, and/or the like or any combination or alloy thereof. In some examples, the material can be made from a memory shape material, such as Nitinol, and the expanded configuration for a first expandable clot engagement section 102 can be made by heat setting the material to the expanded configuration.


In some examples, a stentriever 100 can include a first clot engagement membrane 104 attached to the first expandable clot engagement section 102. The first clot engagement membrane 104 can be a full or partial covering of the first expandable clot engagement section 102 to direct a suction and/or aspirate into the first expandable clot engagement section 102. The material for the first clot engagement membrane 104 can include silicon, polyurethane, polypropylene, polyethersulfone, and/or the like. In some examples, the material for the first clot engagement membrane 104 can be pliable such that the material can be opened as the first expandable clot engagement section 102 opens from a collapsed configuration to an expanded configuration.


A first expandable clot engagement section 102 can include a first clot inlet 106. A first clot inlet 106 can be an opening distal to the first expandable clot engagement section 102 that is not covered by a first clot engagement membrane 104 and provides an area for an occlusive clot to be pulled into the first expandable clot engagement section 102. As will be appreciated, the examples described herein provide a way to capture a clot without relying exclusively on the radial force applied by the expandable sections of the stentriever 100. As suction is applied to the stentriever 100, the clot can be directed along with the flow of aspirate into the first clot inlet 106 via the first clot engagement membrane 104, and continued suction can provide improved grip on the clot.


A stentriever 100 can include a proximal flow channel 108. The proximal flow channel 108 can be positioned proximal to the first expandable clot engagement section 102. The proximal flow channel 108 can have a collapsed configuration and an expanded configuration, similar to the first expandable clot engagement section 102 described above. It is contemplated that the diameter 109 of a proximal flow channel 108 in a collapsed configuration can, similar to the first expandable clot engagement section 102, be less than approximately 1.75 mm so as to fit within a microcatheter for delivery into the vessel.


The proximal flow channel 108 can be a braided tube, laser cut metallic tube, laser cut polymeric tube and/or the like. In some examples, the proximal flow channel 108 can include, but is not limited to, materials such as Nitinol, stainless steel, MP35N, tungsten, and/or the like or any combination or alloy thereof. In some examples, the material can be made from a memory shape material, such as Nitinol, and the expanded configuration for a proximal flow channel 108 can be made by heat setting the material to the expanded configuration.


The proximal flow channel 108 can include a proximal flow membrane 110. The proximal flow membrane 110 can cover an outer surface of the proximal flow channel 108 at a position proximal to the first expandable clot engagement section 102. The proximal flow membrane 110 can direct the flow of aspirate from the first expandable clot engagement section 102 and through the proximal flow channel 108. The flow of the aspirate through the proximal flow channel 108 can increase the suction around the first expandable clot engagement section 102 so as to pull a clot deeper into first clot inlet 106. The material for the proximal flow membrane 110 can be silicon, polyurethane, polypropylene, polyethersulfone, and/or the like. In some examples, the material for the proximal flow membrane 110 can be pliable such that the material can be opened as the proximal flow channel 108 opens from a collapsed configuration to an expanded configuration.


In some examples, the proximal flow channel 108 can be opened into its expanded configuration while deployed into the vessel. Once expanded, the proximal flow channel 108 can have a diameter 109 of approximately equal to the inner diameter of an intermediate or access catheter. For example, once deployed, an intermediate catheter can be advanced into position after the stentriever 100 is deployed within a clot. The intermediate catheter can be directed to the proximal flow channel 108. In some examples, the proximal flow membrane 110 can form a seal with the inner surface of the intermediate catheter. The seal can allow aspiration to be drawn from the first expandable clot engagement section 102, through the membrane-covered proximal flow channel 108, and into the intermediate catheter to further pull the clot into the first clot inlet 106. Intermediate catheters can have an inner diameter of approximately 0.040 inches to approximately 0.120 inches (approximately 1.0 mm to approximately 3.0 mm). Accordingly, it is contemplated that the diameter 109 of a proximal flow channel 108 in an expanded configuration can fall within those ranges.


The proximal flow channel 108 can have a length suitable for engaging with an intermediate catheter which has been forwarded to the vicinity of the clot. In another embodiment, the proximal flow channel can have sufficient length to engage with an intermediate or access catheter which has been parked in the Internal Carotid Artery. It is contemplated that the length of the proximal channel can have a range of approximately 2.0 mm to 100 mm.


A stentriever 100 can include a flexible shaft 112. The shaft 112 can act as a both a delivery mechanism to feed the stentriever 100 into the vessel and as a scaffold or frame for the additional features of the stentriever 100. The expandable clot engagement sections (e.g., first expandable clot engagement section 102) for example, can be connected to and extend from the shaft 112. The shaft can be made from a flexible material, including but not limited to metals and polymers, such that the stentriever 100 can bend as the device is deployed into a vessel.


A stentriever 100 can include a second expandable clot engagement section 114. The second expandable clot engagement section 114 can extend from the shaft 112, similar to the first expandable clot engagement section 102, and be positioned distal to the first expandable clot engagement section 102 on the shaft 112. The second expandable clot engagement section 114 can be similar in all aspects to the first expandable clot engagement section 102. Though the first expandable clot engagement section 102 and second expandable clot engagement section 114 can comprise identical materials and have identical dimension, nothing requires the two sections to be identical. The second expandable clot engagement section 114 can act as a second capturing device, wherein in an expanded configuration, the second expandable clot engagement section 114 can engage the clot within vessel by exerting a radial force upon the clot. Although FIG. 1 depicts a stentriever 100 having two clot engagement section (i.e., first expandable clot engagement section 102 and second expandable clot engagement section 114), a stentriever 100 described herein is not limited to two clot engagement sections, as more than two could be provided.


In some examples, a stentriever 100 can include a second clot engagement membrane 116 attached to the second expandable clot engagement section 114. The second clot engagement membrane 116 can be a full or partial covering of the second expandable clot engagement section 114 to direct a suction and/or aspirate into the second expandable clot engagement section 114. The material for the second clot engagement membrane 116 can be similar to the materials described above for the first clot engagement membrane 104.


A second expandable clot engagement section 114 can include a second clot inlet 118. A second clot inlet 118 can be an opening distal to the second expandable clot engagement section 114 that is not covered by a second clot engagement membrane 116 and provides an area for an occlusive clot to be pulled into the second expandable clot engagement section 114. By providing a first clot inlet 106 and a second clot inlet 118, the clot can be pulled, by providing aspiration to the proximal flow channel 108, into both clot inlets 106,118 for improved grip on the clot.


A shaft 112 of a stentriever 100 can include a distal tip 120. The distal tip 120 can include a rounded and/or smooth end so as to not perforate a wall of a vessel as the stentriever 100 is being deployed within the vessel. In some examples, the distal tip 120 can include radiopaque coil or marker disposed on or in the distal tip 120 for visibility under fluoroscopy. Additional radiopaque coils or markers can be added near the expandable clot engagement sections such that a physician can view the position of the device in relation to the occlusive clot under fluoroscopy.


A stentriever 100 can include a distal engagement section 202 positioned distal to the first expandable clot engagement section 102; when a stentriever 100 includes a second expandable clot engagement section 114, the distal engagement section 202 is distal to the second section. When a physician inserts the stentriever 100 into a vessel, the stentriever 100 can be passed beyond the clot such that the distal engagement section 202 is within the vessel distal to the clot. The distal engagement section 202 can have a collapsed configuration and an expanded configuration, and the dimensions of the distal engagement section 202 in the collapsed configuration and the expanded configuration can be similar to the dimensions described above for the first expandable clot engagement section 102. As will be described below, once expanded, the distal engagement section 202 can expand to fill the cross-sectional area of the vessel and constrict fluid flow through the distal engagement section 202. The materials that can be used for a distal engagement section 202 can include, but are not limited to, Nitinol, stainless steel, MP35N, tungsten, and/or the like or any combination or alloy thereof. In some examples, the material can be made from a memory shape material, such as Nitinol, and the expanded configuration for a distal engagement section 202 can be made by heat setting the material to the expanded configuration.


A distal engagement section 202 can include a distal membrane 204. The distal membrane 204 can be a partial membrane covering of the distal end of the distal engagement section 202. The material for the distal membrane 204 can be silicon, polyurethane, polypropylene, polyethersulfone, and/or the like.


The distal membrane 204 can include one or more distal pores 206. Distal pores 206 can be holes created in the distal membrane 204 to allow flow, albeit limited flow, through the distal membrane 204. The distal pores 206 can be laser cut, stamped, or perforated holes within the material of the distal membrane 204. At least a portion of the distal pores 206 can have a length of less than 500 micrometers from one side of the distal pore 206 to the other. In the case that the distal pores 206 are circular, the circular distal pores 206 can have a diameter of less than 500 micrometers. The length and/or diameter of the distal pores 206 can be altered so as to increase or decrease the amount of flow permitted through the distal pores 206. For example, distal pores 206 can constrict (i.e., partially limit but not necessarily completely restrict) flow of aspirate through the distal engagement section 202. When suction is applied to the proximal flow channel 108 via an intermediate catheter, the constricted flow through the distal pores 206 can create an area of negative pressure between the distal engagement section 202 and the first expandable clot engagement section 102. This negative pressure can increase the suction of the clot into the first clot inlet 106, thereby improving grip on the clot. When a stentriever 100 includes a second expandable clot engagement section 114, the negative pressure provided by the constricted flow can also further pull the clot into a second clot inlet 118.


In some examples, the distal pores 206 can also serve to prevent friable-clot fragments from passing distal to the stentriever 100. As described above, clots are oftentimes fragile and delicate. When a clot is being removed from a vessel, fragments of the clot can dislodge from the body of the occlusion. The distal pores 206 provide a mechanism for preventing the loose fragments from passing distal to the stentriever 100 as the clot and device are removed from the vessel.


A distal engagement section 202 can include a plurality of distal clot cells 208 positioned proximal to the distal membrane 204. The distal clot cells 208 can be part of the frame of the distal engagement section 202. For example, the distal engagement section 202 can be a braided mesh of the materials described above, and the distal clot cells 208 can be the areas between the scaffold of the braided mesh. When the stentriever 100 is removed from the vessel, the distal clot cells 208 can help to grip the clot and prevent the clot from moving distal to the stentriever. The distal clot cells 208 can also provide a mechanism for preventing loose fragments of the clot from passing distal to the stentriever 100 as the clot and device are removed from the vessel.



FIG. 2 is a side-view illustration of an exemplary stentriever 100 interacting with an intermediate catheter 300, according to aspects of the present invention. FIG. 2 depicts an exemplary intermediate catheter 300 being positioned at a proximal flow channel 108, as described above. The intermediate catheter 300 can form a seal with the proximal flow membrane 110 at a proximal seal area 302, thereby allowing suction to be directed from the first expandable clot engagement section 102, into the proximal flow channel 108, and through the intermediate catheter 300. The intermediate catheter 300 can be advanced over the shaft 112, and the proximal end of the shaft 112 can reside within the intermediate catheter 300 when the catheter is proximate the proximal flow channel 108.



FIG. 3 is a side-view illustration of an exemplary stentriever 100 having an intermediate flow channel 402, according to aspects of the present invention. A stentriever 100 can include an intermediate flow channel 402 positioned proximal to and adjacent the second expandable clot engagement section 114. The intermediate flow channel 402 can have a collapsed configuration and an expanded configuration, similar to the configurations described above for the proximal flow channel 108. The dimensions of an intermediate flow channel 402 can also be similar to the dimensions of a proximal flow channel 108. The intermediate flow channel can be a braided tube, laser cut metallic tube, laser cut polymeric tube and/or the like. In some examples, the intermediate flow channel 402 can include, but is not limited to, materials such as Nitinol, stainless steel, MP35N, tungsten, and/or the like or any combination or alloy thereof. In some examples, the material can be made from a memory shape material, such as Nitinol, and the expanded configuration for an intermediate flow channel 402 can be made by heat setting the material to the expanded configuration.


An intermediate flow channel 402 can include a membrane, similar to the proximal flow membrane 110 described above for the proximal flow channel 108. The intermediate flow channel 402 can direct a flow of aspirate from the second expandable clot engagement section 114 to a position proximal to the second expandable clot engagement section 114. The flow of the aspirate through the intermediate flow channel 402 can be used to localize the suction upon the clot. For example, an intermediate flow channel 402 can allow the aspirate suction to be directed to the second clot inlet 118, further improving the grip on the clot. In some examples, a certain amount of open space can be disposed between the proximal end of the intermediate flow channel 402 and the first clot inlet 106 (as shown in the figure) such that the first clot inlet 106 has room to capture at least a portion of the clot.



FIG. 4 is a top-view illustration of an exemplary stentriever 100, according to aspects of the present invention. This view of a stentriever 100 provides an alternative view of the stentriever 100 shown in FIG. 1. As can be seen, the first clot inlet 106 (and the second clot inlet 118, when provided) can remain open and without a membrane covering. This allows the clot to enter the uncovered area and be captured within the inlets.



FIG. 5A is a side-view illustration of an exemplary stentriever 100 having an inner channel 404, according to aspects of the present invention. In some examples, a stentriever 100 can include an inner channel 404 that extends from the proximal end of the device to the distal engagement section 202. FIG. 5A depicts an exemplary stentriever 100 without membranes on the first expandable clot engagement section 102, the second expandable clot engagement section 114, or the distal engagement section 202. The absence of the membranes in the view provides an unobstructed view of an exemplary inner channel 404. An inner channel 404 can have a collapsed configuration and an expanded configuration, similar to the configurations described above for the proximal flow channel 108. An inner channel 404 can, in some examples, be an extension of the proximal flow channel 108. In these examples, the proximal flow channel 108—inner channel 404 combination can extend from the area proximal to the first expandable clot engagement section 102 to the distal engagement section 202. The proximal flow channel 108 can include a membrane (e.g., proximal flow membrane 110) extending to the first clot inlet 106 to help direct the aspirate and/or suction, as described herein.



FIG. 5B is a side-view illustration of an exemplary inner channel 404, according to aspects of the present invention. This view shows an exemplary inner channel 404 without the expandable sections for contacting a clot, and thus provides a detailed view of the inner channel 404. An inner channel 404 can be a braided tube, laser cut metallic tube, laser cut polymeric tube and/or the like. In some examples, the inner channel 404 can include, but is not limited to, materials such as Nitinol, stainless steel, MP35N, tungsten, and/or the like or any combination or alloy thereof. In some examples, the material can be made from a memory shape material, such as Nitinol, and the expanded configuration for an inner channel 404 can be made by heat setting the material to the expanded configuration.


The inner channel 404 can include inner channel membranes 406 at positions along the length of the inner channel 404. The inner channel membranes 406 can be made similar materials as those described for the proximal flow membrane 110 above. The inner channel membranes 406 can be positioned at locations on the length of the inner channel 404 to correspond with the one or more clot engagement sections described above. For example, an inner channel membrane 406 can be positioned proximate a second expandable clot engagement section 114 (not shown in the figure) such that aspirate can be directed from the second expandable clot engagement section 114, into the inner channel membrane 406, and proximal in the device. In some examples, an inner channel membrane 406 can be provided proximate the distal engagement section 202 (not shown in the figure) to direct flow from the distal engagement section 202.


In some examples, the inner channel 404 can include a plurality of inner channel pores 408 within the surface of the inner channel 404. The inner channel pores 408 can be openings that allow fluid to flow from an area outside of the inner channel 404 to an area inside the inner channel 404. The inner channel pores 408 can extend from the proximal flow membrane 110 to the end of the inner channel 404; in examples with one or more inner channel membranes 406, the inner channel pores 408 can reside in areas not covered with membrane material. In some examples, the inner channel pores 408 can be cut, etched, drilled, or the like into the surface of the inner channel 404. In other examples, the inner channel pores 408 can be inherent features of the inner channel 404 material. For example, if an inner channel 404 is a braided tube or the like, the inner channel pores 408 can be the area between the braids of the material. The inner channel pores 408 can serve to prevent large clot fragments from entering the inner channel 404, thereby preventing the stentriever 100 from clogging. Clogging of the proximal end of the stentriever 100 could degrade the suction described herein that improves the grip on the clot. It is contemplated that the inner channel pores 408 can have a length and/or diameter (depending on the shape of the particular inner channel pore 408) that is from approximately 200 micrometers to approximately 1.50 mm (e.g., from approximately 200 micrometers to approximately 500 micrometers; from approximately 500 micrometers to approximately 800 micrometers; from approximately 800 micrometers to approximately 1.20 mm; or from approximately 1.20 mm to approximately 1.50 mm). These dimensions can prevent large clot fragments from entering the inner channel 404 and clogging the suction but can also allow small fragments to be aspirated and removed from the area (e.g., through the proximal flow channel 108 and intermediate catheter 300).



FIG. 6 is a perspective-view illustration of an exemplary stentriever 100 with a full-length inner channel 404, according to aspects of the present invention. The exemplary stentriever 100 in FIG. 6 shows that the examples shown in FIGS. 1-5A are merely exemplary and are not inclusive of all designs contemplated herein. In some examples, a stentriever 100 can include an inner channel 404 that extends from the proximal flow channel 108 to the distal engagement section 202. It is also contemplated that an inner channel 404 can extend only partially across the length of the device, for example only to a second expandable clot engagement section 114 (or a third section, etc.). FIG. 6 also shows an example stentriever 100 wherein only the proximal flow channel 108 includes a membrane (i.e., proximal flow membrane 110), while the remainder of the length of the inner channel 404 does not include a membrane, which is in accordance with some examples.



FIGS. 7A and 7B are illustrations of an exemplary frame 504 for a stentriever, according to aspects of the present invention. In some examples, the expandable clot engagement sections (i.e., first expandable clot engagement section 102, second expandable clot engagement section 114, distal engagement section 202, etc.) can be attached to a frame 504. The frame 504 can be attached to and extend from the shaft 112, as shown in FIG. 7B, to create the expanded construct described herein. In some examples, a full-length or partial-length inner channel 404 (e.g., the inner channel shown in FIG. 5B) can be provided to extend along the length of the shaft 112 and inside the frame 504. The frame 504 can include any of the features described herein.


In some examples, the distal end of the distal engagement section 202 can, in lieu of distal pores 206 (as shown in FIGS. 1-4), include a distal flow aperture 502. The distal flow aperture 502 can be an area of the distal engagement section 202 that is not covered with distal membrane 204 so as to constrict the flow of aspirate through the distal engagement section 202.



FIG. 8 is an end view of a partially-open distal engagement section 202, according to aspects of the present invention. As described above, the constriction of flow through the distal engagement section 202 can create a negative pressure proximal to the distal engagement section 202, thereby increasing the grip on the clot. The distal flow apertures 502 can be partial openings in the distal membrane 204 that allows a limited amount of fluid flow through the distal membrane 204.



FIGS. 9A-9F depict an exemplary method of deploying a stentriever 100 and removing an occlusive clot 10 from a vessel 12, according to aspects of the present invention. FIG. 9A shows a clot 10 occluding a vessel 12. In FIG. 9B, a guide wire 602 can be fed through the vessel 12 and across the clot 10. A microcatheter 600 can then be advanced over the guide wire 602 and distal to the clot 10. The guide wire 602 can then be removed from within the cannulated microcatheter 600.


As shown in FIG. 9C, the stentriever 100 can be advanced through the microcatheter 600 in its collapsed configuration until the distal tip 120 of the device reaches the distal end of the microcatheter 600. As shown in FIG. 9D, the microcatheter 600 can then be retracted proximally while the position of the stentriever 100 is maintained. Upon retracting the microcatheter 600, the stentriever 100 can be unsheathed to allow the stentriever 100 to expand into its expanded configuration. In FIG. 9D, only the distal engagement section 202 has been unsheathed.


As shown in FIG. 9E, once the stentriever 100 is unsheathed and fully expanded, an intermediate catheter 300 can be advanced, for example over the microcatheter and/or along the shaft of the stentriever 100, to the proximal flow channel 108. As described above, the proximal flow channel 108 can include a membrane that allows the intermediate catheter to form a seal against the proximal flow channel 108.


As shown in FIGS. 9F and 9G, aspiration can be applied to the intermediate catheter 300. The flow of fluid 16 can be directed by the membrane-covered first expandable clot engagement section 102 (and second expandable clot engagement section 114, as shown in the figure), to pull the clot 10 into the engagement sections. The distal engagement section 202 can include distal pores 206 or distal flow apertures 502, as described herein, to constrict the flow of fluid 16 through the distal engagement section 202. The constricted flow 604 of fluid 16 through the distal engagement section 202 can create a negative pressure area 606 near the expandable clot engagement sections 102,114, which can facilitate pulling the clots into the sections 102,114.


As shown in FIG. 9H, once suction is applied to the proximal flow channel 108 and the clot 10 has been sufficiently captured, the clot 10 can be pulled into the intermediate catheter 300 to be removed from the vessel 12. The position of the intermediate catheter 300 can be maintained, and continued aspiration can be provided to aspirate any clot fragments 14 that may have migrated distal to the stentriever 100, as shown in FIG. 9I. In some examples, the intermediate catheter 300 can be removed along with the stentriever 100 and clot 10 as a single unit through a guide or access catheter.



FIGS. 10A-12B are flow diagrams illustrating methods of removing an occlusive clot with a stentriever. These method steps can be implemented by any of the example means described herein or by similar means, as will be appreciated.


Referring to method 1000 as outlined in FIG. 10A, in step 1010, a stentriever can be delivered into a vessel and across a clot. The stentriever can include a shaft extending between a proximal end and a distal end. An expandable clot engagement section can extend from the shaft. The expandable clot engagement section can include a clot engagement membrane directing a fluid into the engagement section. A clot inlet can be provided in the engagement section for capturing a clot. The stentriever can also include a proximal flow channel with a proximal flow membrane, as described herein. In step 1020, the stentriever can be unsheathed, for example from an access sheath or a microcatheter, to expand the stentriever. Upon expansion of the stentriever, the expandable clot engagement section can engage the clot. In step 1030, an intermediate catheter can be advanced into the vessel and to the proximal flow channel of the stentriever. As described herein, the inner surface of the intermediate catheter can create a seal with the proximal flow membrane. In step 1040, aspiration can be applied to the intermediate catheter such that a flow of fluid is directed by the clot engagement membrane into and into the proximal flow channel to pull the clot into the clot inlet. In step 1050, the stentriever can be pulled proximally to remove the clot from the vessel.


The method 1000 illustrated in FIG. 10A can further include one or more of the steps outlined in FIG. 10B. Referring to method 1060 as outlined in FIG. 10B, in step 1070, the flow of aspiration at the clot engagement section can be constricted by distal pores of a distal engagement section. The constriction of the flow can create a negative pressure near the clot engagement section to pull the clot into the clot inlet. In step 1080, friable-clot fragments can be prevented from passing distal to the stentriever by a plurality of distal clot cells in the distal engagement section and/or the distal pores of the distal engagement section.


The methods 1000 and 1060 as illustrated in FIGS. 10A and 10B can further include one or more of the steps outlined in FIG. 11. Referring to method 1100 as outlined in FIG. 11, in step 1110, a guide wire can be delivered across an occlusive clot. In step 1120, a microcatheter can be advanced along the guide wire and across the clot 10. In step 1130, the guide wire can be removed from the microcatheter, leaving the microcatheter in place within the vessel. In step 1140, a stentriever, as described herein, can be advanced through the microcatheter in a collapsed configuration. In step 1150, the microcatheter can be pulled proximal (i.e., retracted) to allow the stentriever to expand into an expanded configuration, thereby exerting an outward radial force on the clot.


The methods 1000, 1060, and 1100, as illustrated in FIGS. 10A-11 can further include one or more of the steps outlined in FIG. 12A. Referring to method 1200a as outlined in FIG. 12A, in step 1210, the clot can be captured within the stentriever (i.e., within a clot inlet of the stentriever), and the stentriever and the clot can be pulled into the intermediate catheter. In step 1220, the stentriever and captured clot can be removed from the intermediate catheter, leaving the intermediate catheter in place. In step 1230, with the intermediate catheter in place within the vessel, suction can be provided to the intermediate catheter to aspirate any remaining clot fragments in the vessel.


As an alternative to the steps provided in method 1200a as outlined in FIG. 12A, one or more of the steps outlined in FIG. 12B can be performed. Referring to method 1200b, in step 1240, the clot can be captured within the stentriever (i.e., within a clot inlet of the stentriever), and the stentriever and the clot can be pulled into the intermediate catheter. In step 1250, the stentriever, clot, and intermediate catheter can be removed via a guide catheter or an access sheath.


The descriptions contained herein are examples of embodiments of the invention and are not intended in any way to limit the scope of the invention. As described herein, the invention contemplates many variations and modifications of the stentriever device including using alternative geometries of structural elements, combining shapes and structural elements from various example embodiments, using alternative materials, etc. These modifications would be apparent to those having ordinary skill in the art to which this invention relates and are intended to be within the scope of the claims which follow.

Claims
  • 1. A stentriever for removing a clot from a vessel, comprising: a shaft extending between a proximal end and a distal end;a first expandable clot engagement section directly connected to and extending from the shaft and comprising a first clot engagement membrane directing an aspiration into the first expandable clot engagement section;a second expandable clot engagement section extending from the shaft and positioned distal to the first expandable clot engagement section;an intermediate flow channel positioned proximal to and adjacent the second expandable clot engagement section;a proximal flow channel positioned proximal to and adjacent the first expandable clot engagement section, the proximal flow channel comprising a proximal flow membrane directing the aspiration from the first expandable clot engagement section and to the proximal flow channel; anda distal engagement section positioned distal to the first expandable clot engagement section and extending from the shaft,wherein the stentriever comprises a collapsed configuration to be inserted into a microcatheter,wherein the stentriever comprises an expanded configuration for exerting an outward radial force on the clot, andwherein, when the stentriever is in the expanded configuration, the first expandable clot engagement section has a larger diameter than the proximal flow channel, causing the aspiration to be directed from the first expandable clot engagement section by the first clot engagement membrane and into the proximal flow channel.
  • 2. The stentriever of claim 1, wherein the first expandable clot engagement section further comprises a first clot inlet capturing the clot.
  • 3. The stentriever of claim 1, wherein the proximal flow channel comprises: a collapsed configuration to be inserted into the microcatheter, andan expanded configuration wherein the proximal flow channel exerts a radial force on an intermediate catheter,wherein, in the expanded configuration, the proximal flow membrane engages with an inner surface of the intermediate catheter at a proximal seal area to direct aspiration flow.
  • 4. The stentriever of claim 1, wherein the second expandable clot engagement section comprises a second clot engagement membrane directing the aspiration into the second expandable clot engagement section.
  • 5. The stentriever of claim 1, wherein the distal engagement section comprises a plurality of distal clot cells capturing clot fragments.
  • 6. The stentriever of claim 5, wherein the distal engagement section comprises a distal membrane, and wherein the distal membrane comprises distal pores constricting flow of the aspiration into the distal engagement section.
  • 7. The stentriever of claim 6, wherein: the first expandable clot engagement section further comprises a first clot inlet capturing the clot, andthe distal membrane constricts flow from the distal engagement section to the proximal flow channel to create a negative pressure at the first expandable clot engagement section, thereby pulling the clot into the first clot inlet.
  • 8. A system for removing a clot from a vessel, the system comprising: a stentriever comprising: a shaft extending between a proximal end and a distal end;a first expandable clot engagement section directly connected to and extending from the shaft and comprising a first clot engagement membrane directing an aspiration into the first expandable clot engagement section;a second expandable clot engagement section extending from the shaft and positioned distal to the first expandable clot engagement section;an intermediate flow channel positioned proximal to and adjacent the second expandable clot engagement section;a proximal flow channel positioned proximal to and adjacent the first expandable clot engagement section, the proximal flow channel comprising a proximal flow membrane; anda distal engagement section positioned distal to the first expandable clot engagement section and extending from the shaft; andan intermediate catheter,wherein the stentriever comprises a collapsed configuration to be inserted into a microcatheter,wherein the stentriever comprises an expanded configuration to be expanded in the vessel,wherein, in the expanded configuration, the proximal flow channel exerts a radial force on the intermediate catheter,wherein the proximal flow membrane seals against an inner surface of the intermediate catheter, andwherein, when the stentriever is in the expanded configuration, the first expandable clot engagement section has a larger diameter than the proximal flow channel, causing the aspiration to be directed from the first expandable clot engagement section by the first clot engagement membrane and into the proximal flow channel.
  • 9. The system of claim 8, wherein the first expandable clot engagement section further comprises a first clot inlet capturing the clot.
  • 10. The system of claim 8, wherein the second expandable clot engagement section comprises a second clot engagement membrane directing an aspiration into the second expandable clot engagement section.
  • 11. The system of claim 8, wherein the distal engagement section comprises a plurality of distal pores constricting flow of the aspiration into the distal engagement section.
  • 12. A stentriever for removing a clot from a vessel, comprising: a shaft extending between a proximal end and a distal end;a first expandable clot engagement section directly connected to and extending from the shaft and comprising a first clot engagement membrane directing an aspiration into the first expandable clot engagement section;a second expandable clot engagement section extending from the shaft, the second expandable clot engagement section being positioned distal to the first expandable clot engagement section, the second expandable clot engagement section comprising a second clot engagement membrane directing the aspiration into the second expandable clot engagement section;a distal engagement section positioned distal to the first expandable clot engagement section and the second expandable clot engagement section and extending from the shaft; andan inner channel extending from a position proximal to and adjacent the first expandable clot engagement section to a position proximate the distal engagement section, the inner channel comprising: a first inner channel membrane positioned along a length of the inner channel proximal to and adjacent the first expandable clot engagement section; anda second inner channel membrane positioned along the length of the inner channel proximal to and adjacent the second expandable clot engagement section, the second inner channel membrane being separated from the first inner channel membrane along a length of the inner channel,wherein the stentriever comprises a collapsed configuration to be inserted into a microcatheter,wherein the stentriever comprises an expanded configuration for exerting an outward radial force on the clot, andwherein, when the stentriever is in the expanded configuration, the first expandable clot engagement section has a larger diameter than the inner channel, causing the aspiration to be directed from the first expandable clot engagement section by the first clot engagement membrane and into the first inner channel membrane.
  • 13. The stentriever of claim 12, wherein the distal engagement section comprises a plurality of distal clot cells capturing clot fragments.
  • 14. The stentriever of claim 13, wherein the distal engagement section comprises a distal membrane, and wherein the distal membrane comprises distal pores constricting flow of the aspiration into the distal engagement section.
US Referenced Citations (878)
Number Name Date Kind
4455717 Gray Jun 1984 A
4611594 Grayhack et al. Sep 1986 A
4612931 Dormia Sep 1986 A
4727873 Mobin-Uddin Mar 1988 A
4793348 Palmaz Dec 1988 A
4873978 Ginsburg Oct 1989 A
5011488 Ginsburg Apr 1991 A
5084065 David et al. Jan 1992 A
5092839 Kipperman Mar 1992 A
5100423 Fearnot Mar 1992 A
5102415 Guenther et al. Apr 1992 A
5108419 Reger et al. Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5163951 Pinchuk et al. Nov 1992 A
5171233 Amplatz et al. Dec 1992 A
5171259 Inoue Dec 1992 A
5217441 Shichman Jun 1993 A
5234437 Sepetka Aug 1993 A
5236447 Kubo et al. Aug 1993 A
5330482 Gibbs et al. Jul 1994 A
5383887 Nadal Jan 1995 A
5387219 Rappe Feb 1995 A
5387226 Miraki Feb 1995 A
5449372 Schmaltz et al. Sep 1995 A
5499985 Hein et al. Mar 1996 A
5538512 Zenzon et al. Jul 1996 A
5538515 Kafry et al. Jul 1996 A
5549626 Miller et al. Aug 1996 A
5558652 Henke Sep 1996 A
5609627 Goicoechea et al. Mar 1997 A
5624461 Mariant Apr 1997 A
5639277 Mariant et al. Jun 1997 A
5639278 Dereume et al. Jun 1997 A
5645558 Horton Jul 1997 A
5653605 Woehl et al. Aug 1997 A
5658296 Bates et al. Aug 1997 A
5665117 Rhodes Sep 1997 A
5695519 Summers et al. Dec 1997 A
5709704 Nott et al. Jan 1998 A
5713853 Clark et al. Feb 1998 A
5769871 Mers Kelly et al. Jun 1998 A
5769884 Solovay Jun 1998 A
5779686 Sato et al. Jul 1998 A
5779716 Cano et al. Jul 1998 A
5800519 Sandock Sep 1998 A
5810874 Lefebvre Sep 1998 A
5814064 Daniel Sep 1998 A
5827304 Hart Oct 1998 A
5853422 Huebsch et al. Dec 1998 A
5855598 Pinchuk Jan 1999 A
5893869 Barnhart et al. Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5897567 Ressemann et al. Apr 1999 A
5904698 Thomas et al. May 1999 A
5911702 Romley et al. Jun 1999 A
5911725 Boury Jun 1999 A
5919126 Armini Jul 1999 A
5931509 Bartholomew Aug 1999 A
5935139 Bates Aug 1999 A
5947995 Samuels Sep 1999 A
6063113 Kavteladze et al. May 2000 A
6066149 Samson et al. May 2000 A
6066158 Engelson et al. May 2000 A
6093196 Okada Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096053 Bates Aug 2000 A
6099534 Bates et al. Aug 2000 A
6099559 Nolting Aug 2000 A
6102932 Kurz Aug 2000 A
6106548 Roubin et al. Aug 2000 A
6129739 Khosravi Oct 2000 A
6143022 Shull et al. Nov 2000 A
6146404 Kim et al. Nov 2000 A
6156064 Chouinard Dec 2000 A
6165194 Denardo Dec 2000 A
6165199 Barbut Dec 2000 A
6168604 Cano Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6174318 Bates et al. Jan 2001 B1
6179861 Khosravi et al. Jan 2001 B1
6203561 Ramee et al. Mar 2001 B1
6214026 Lepak et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6231597 Deem et al. May 2001 B1
6238412 Dubrul et al. May 2001 B1
6245012 Kleshinski Jun 2001 B1
6245087 Addis Jun 2001 B1
6251122 Tsukernik Jun 2001 B1
6254571 Hart Jul 2001 B1
6264663 Cano Jul 2001 B1
6267777 Bosma et al. Jul 2001 B1
6290710 Cryer et al. Sep 2001 B1
6312444 Barbut Nov 2001 B1
6315778 Gambale et al. Nov 2001 B1
6325815 Kusleika et al. Dec 2001 B1
6325819 Pavcnik et al. Dec 2001 B1
6334864 Amplatz et al. Jan 2002 B1
6336934 Gilson et al. Jan 2002 B1
6346116 Brooks et al. Feb 2002 B1
6348056 Bates et al. Feb 2002 B1
6350271 Kurz et al. Feb 2002 B1
6355057 DeMarais et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6375670 Greenhalgh Apr 2002 B1
6383205 Samson et al. May 2002 B1
6383206 Gillick et al. May 2002 B1
6391037 Greenhalgh May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6416541 Denardo Jul 2002 B2
6425909 Dieck et al. Jul 2002 B1
6428558 Jones et al. Aug 2002 B1
6432122 Gilson et al. Aug 2002 B1
6436112 Wensel et al. Aug 2002 B2
6458139 Palmer et al. Oct 2002 B1
6485497 Wensel et al. Nov 2002 B2
6485501 Green Nov 2002 B1
6485502 Don Michael et al. Nov 2002 B2
6488701 Nolting et al. Dec 2002 B1
6511492 Rosenbluth et al. Jan 2003 B1
6530935 Wensel et al. Mar 2003 B2
6530939 Hopkins et al. Mar 2003 B1
6540768 Diaz et al. Apr 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6551341 Boylan et al. Apr 2003 B2
6551342 Shen et al. Apr 2003 B1
6575996 Denison et al. Jun 2003 B1
6575997 Palmer et al. Jun 2003 B1
6582448 Boyle et al. Jun 2003 B1
6585756 Strecker Jul 2003 B1
6589265 Palmer et al. Jul 2003 B1
6592607 Palmer et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6592616 Stack et al. Jul 2003 B1
6602265 Dubrul et al. Aug 2003 B2
6602271 Adams et al. Aug 2003 B2
6602272 Boylan et al. Aug 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6616679 Khosravi et al. Sep 2003 B1
6632241 Hancock et al. Oct 2003 B1
6638245 Miller et al. Oct 2003 B2
6638293 Makower et al. Oct 2003 B1
6641590 Palmer et al. Nov 2003 B1
6656218 Denardo et al. Dec 2003 B1
6660021 Palmer et al. Dec 2003 B1
6663650 Sepetka et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6685722 Rosenbluth et al. Feb 2004 B1
6692504 Kurz et al. Feb 2004 B2
6692508 Wensel et al. Feb 2004 B2
6692509 Wensel et al. Feb 2004 B2
6695858 Dubrul et al. Feb 2004 B1
6702782 Miller et al. Mar 2004 B2
6709465 Mitchell et al. Mar 2004 B2
6712834 Yassour et al. Mar 2004 B2
6726701 Gilson et al. Apr 2004 B2
6726703 Broome et al. Apr 2004 B2
6730104 Sepetka et al. May 2004 B1
6783528 Vincent-Prestigiacomo Aug 2004 B2
6783538 McGuckin, Jr. et al. Aug 2004 B2
6824545 Sepetka et al. Nov 2004 B2
6855155 Denardo et al. Feb 2005 B2
6878163 Denardo et al. Apr 2005 B2
6890340 Duane May 2005 B2
6913612 Palmer et al. Jul 2005 B2
6913618 Denardo et al. Jul 2005 B2
6939361 Kleshinski Sep 2005 B1
6953472 Palmer et al. Oct 2005 B2
6989019 Mazzocchi et al. Jan 2006 B2
6989021 Bosma et al. Jan 2006 B2
6994718 Groothuis et al. Feb 2006 B2
7004954 Voss et al. Feb 2006 B1
7004955 Shen et al. Feb 2006 B2
7004956 Palmer et al. Feb 2006 B2
7008434 Kurz et al. Mar 2006 B2
7033376 Tsukernik Apr 2006 B2
7041116 Goto et al. May 2006 B2
7048758 Boyle et al. May 2006 B2
7052500 Bashiri et al. May 2006 B2
7058456 Pierce Jun 2006 B2
7063707 Bose et al. Jun 2006 B2
7083633 Morrill et al. Aug 2006 B2
7083822 Brightbill Aug 2006 B2
7094249 Broome et al. Aug 2006 B1
7097653 Freudenthal et al. Aug 2006 B2
7101380 Khachin et al. Sep 2006 B2
7172614 Boyle et al. Feb 2007 B2
7175655 Molaei Feb 2007 B1
7179273 Palmer et al. Feb 2007 B1
7185922 Takayanagi et al. Mar 2007 B2
7220271 Clubb et al. May 2007 B2
7226464 Garner et al. Jun 2007 B2
7229472 DePalma et al. Jun 2007 B2
7241304 Boyle et al. Jul 2007 B2
7288112 Denardo et al. Oct 2007 B2
7300458 Henkes et al. Nov 2007 B2
7306618 Demond et al. Dec 2007 B2
7314483 Landau et al. Jan 2008 B2
7316692 Huffmaster Jan 2008 B2
7323001 Clubb et al. Jan 2008 B2
7331976 McGuckin, Jr. et al. Feb 2008 B2
7344550 Carrison et al. Mar 2008 B2
7399308 Borillo et al. Jul 2008 B2
7410491 Hopkins et al. Aug 2008 B2
7425215 Boyle et al. Sep 2008 B2
7452496 Brady et al. Nov 2008 B2
7491215 Vale et al. Feb 2009 B2
7491216 Brady Feb 2009 B2
7510565 Gilson et al. Mar 2009 B2
7534252 Sepetka et al. May 2009 B2
7556636 Mazzocchi et al. Jul 2009 B2
7582111 Krolik et al. Sep 2009 B2
7594926 Linder et al. Sep 2009 B2
7604649 McGuckin, Jr. et al. Oct 2009 B2
7604650 Bergheim Oct 2009 B2
7618434 Santra et al. Nov 2009 B2
7662165 Gilson et al. Feb 2010 B2
7670356 Mazzocchi et al. Mar 2010 B2
7678123 Chanduszko Mar 2010 B2
7691121 Rosenbluth et al. Apr 2010 B2
7691124 Balgobin Apr 2010 B2
7708770 Linder et al. May 2010 B2
7717929 Fallman May 2010 B2
7736385 Agnew Jun 2010 B2
7758606 Streeter et al. Jul 2010 B2
7758611 Kato Jul 2010 B2
7766934 Pal et al. Aug 2010 B2
7771452 Pal et al. Aug 2010 B2
7780694 Palmer et al. Aug 2010 B2
7780700 Frazier et al. Aug 2010 B2
7811305 Balgobin et al. Oct 2010 B2
7815659 Conlon et al. Oct 2010 B2
7819893 Brady et al. Oct 2010 B2
7828815 Mazzocchi et al. Nov 2010 B2
7828816 Mazzocchi et al. Nov 2010 B2
7833240 Okushi et al. Nov 2010 B2
7842053 Chanduszko et al. Nov 2010 B2
7846175 Bonnette et al. Dec 2010 B2
7846176 Gilson et al. Dec 2010 B2
7850708 Pal Dec 2010 B2
7883516 Huang et al. Feb 2011 B2
7887560 Kusleika Feb 2011 B2
7901426 Gilson et al. Mar 2011 B2
7914549 Morsi Mar 2011 B2
7922732 Mazzocchi et al. Apr 2011 B2
7927784 Simpson Apr 2011 B2
7931659 Bose et al. Apr 2011 B2
7998165 Huffmaster Aug 2011 B2
8002822 Glocker et al. Aug 2011 B2
8021379 Thompson et al. Sep 2011 B2
8021380 Thompson et al. Sep 2011 B2
8043326 Hancock et al. Oct 2011 B2
8048151 OBrien et al. Nov 2011 B2
8052640 Fiorella et al. Nov 2011 B2
8057497 Raju et al. Nov 2011 B1
8057507 Horan et al. Nov 2011 B2
8066757 Ferrera et al. Nov 2011 B2
8070791 Ferrera et al. Dec 2011 B2
8088140 Ferrera et al. Jan 2012 B2
8100935 Rosenbluth et al. Jan 2012 B2
8109941 Richardson Feb 2012 B2
8118829 Garrison et al. Feb 2012 B2
8118856 Schreck et al. Feb 2012 B2
8123769 Osborne Feb 2012 B2
8137376 Clubb et al. Mar 2012 B2
8137377 Palmer et al. Mar 2012 B2
8142422 Makower et al. Mar 2012 B2
8142442 Palmer et al. Mar 2012 B2
8182508 Magnuson et al. May 2012 B2
8187298 Pal May 2012 B2
8246641 Osborne et al. Aug 2012 B2
8246672 Osborne Aug 2012 B2
8252017 Paul, Jr. et al. Aug 2012 B2
8252018 Valaie Aug 2012 B2
8262689 Schneiderman et al. Sep 2012 B2
8282668 McGuckin, Jr. et al. Oct 2012 B2
8298257 Sepetka et al. Oct 2012 B2
RE43882 Hopkins et al. Dec 2012 E
8357178 Grandfield et al. Jan 2013 B2
8357179 Grandfield et al. Jan 2013 B2
8357180 Feller, III et al. Jan 2013 B2
8357893 Xu et al. Jan 2013 B2
8361095 Osborne Jan 2013 B2
8361110 Chanduszko Jan 2013 B2
8366663 Fiorella et al. Feb 2013 B2
8409215 Sepetka et al. Apr 2013 B2
8414482 Belson Apr 2013 B2
8414543 McGuckin, Jr. et al. Apr 2013 B2
8419748 Valaie Apr 2013 B2
8460312 Bose et al. Jun 2013 B2
8460313 Huffmaster Jun 2013 B2
8486104 Samson et al. Jul 2013 B2
8512352 Martin Aug 2013 B2
8529596 Grandfield et al. Sep 2013 B2
8545526 Martin et al. Oct 2013 B2
8574262 Ferrera et al. Nov 2013 B2
8579915 French et al. Nov 2013 B2
8585713 Ferrera et al. Nov 2013 B2
8608761 Osborne et al. Dec 2013 B2
8679142 Slee et al. Mar 2014 B2
8690907 Janardhan et al. Apr 2014 B1
8696622 Fiorella et al. Apr 2014 B2
8702652 Fiorella et al. Apr 2014 B2
8702704 Shelton, IV et al. Apr 2014 B2
8702724 Olsen et al. Apr 2014 B2
8777976 Brady et al. Jul 2014 B2
8777979 Shrivastava et al. Jul 2014 B2
8784434 Rosenbluth et al. Jul 2014 B2
8784441 Rosenbluth et al. Jul 2014 B2
8795305 Martin et al. Aug 2014 B2
8795317 Grandfield et al. Aug 2014 B2
8795345 Grandfield et al. Aug 2014 B2
8814892 Galdonik et al. Aug 2014 B2
8814925 Hilaire et al. Aug 2014 B2
8852205 Brady et al. Oct 2014 B2
8870941 Evans et al. Oct 2014 B2
8900265 Ulm, III Dec 2014 B1
8920358 Levine et al. Dec 2014 B2
8939991 Krolik et al. Jan 2015 B2
8945143 Ferrera et al. Feb 2015 B2
8945160 Krolik et al. Feb 2015 B2
8945169 Pal Feb 2015 B2
8945172 Ferrera et al. Feb 2015 B2
8956399 Cam et al. Feb 2015 B2
8968330 Rosenbluth et al. Mar 2015 B2
9011481 Aggerholm et al. Apr 2015 B2
9039749 Shrivastava et al. May 2015 B2
9072537 Grandfield et al. Jul 2015 B2
9095342 Becking et al. Aug 2015 B2
9113936 Palmer et al. Aug 2015 B2
9119656 Bose et al. Sep 2015 B2
9138307 Valaie Sep 2015 B2
9155552 Ulm, III Oct 2015 B2
9161758 Figulla et al. Oct 2015 B2
9161766 Slee et al. Oct 2015 B2
9173668 Ulm, III Nov 2015 B2
9186487 Dubrul et al. Nov 2015 B2
9198687 Fulkerson et al. Dec 2015 B2
9204887 Cully et al. Dec 2015 B2
9211132 Bowman Dec 2015 B2
9232992 Heidner Jan 2016 B2
9254371 Martin et al. Feb 2016 B2
9301769 Brady et al. Apr 2016 B2
9332999 Ray et al. May 2016 B2
9402707 Brady et al. Aug 2016 B2
9445829 Brady et al. Sep 2016 B2
9456834 Folk Oct 2016 B2
9532792 Galdonik et al. Jan 2017 B2
9532873 Kelley Jan 2017 B2
9533344 Monetti et al. Jan 2017 B2
9539011 Chen et al. Jan 2017 B2
9539022 Bowman Jan 2017 B2
9539122 Burke et al. Jan 2017 B2
9539382 Nelson Jan 2017 B2
9549830 Bruszewski et al. Jan 2017 B2
9554805 Tompkins et al. Jan 2017 B2
9561125 Bowman et al. Feb 2017 B2
9572982 Burnes et al. Feb 2017 B2
9579104 Beckham et al. Feb 2017 B2
9579484 Barnell Feb 2017 B2
9585642 Dinsmoor et al. Mar 2017 B2
9615832 Bose et al. Apr 2017 B2
9615951 Bennett et al. Apr 2017 B2
9622753 Cox Apr 2017 B2
9636115 Henry et al. May 2017 B2
9636439 Chu et al. May 2017 B2
9642639 Brady et al. May 2017 B2
9642675 Werneth et al. May 2017 B2
9655633 Leynov et al. May 2017 B2
9655645 Staunton May 2017 B2
9655989 Cruise et al. May 2017 B2
9662129 Galdonik et al. May 2017 B2
9662238 Dwork et al. May 2017 B2
9662425 Lilja et al. May 2017 B2
9668898 Wong Jun 2017 B2
9675477 Thompson Jun 2017 B2
9675782 Connolly Jun 2017 B2
9676022 Ensign Jun 2017 B2
9692557 Murphy Jun 2017 B2
9693852 Lam et al. Jul 2017 B2
9700262 Janik et al. Jul 2017 B2
9700399 Acosta-Acevedo Jul 2017 B2
9717421 Griswold et al. Aug 2017 B2
9717500 Tieu et al. Aug 2017 B2
9717502 Teoh et al. Aug 2017 B2
9724103 Cruise et al. Aug 2017 B2
9724526 Strother et al. Aug 2017 B2
9750565 Bloom et al. Sep 2017 B2
9757260 Greenan Sep 2017 B2
9764111 Gulachenski Sep 2017 B2
9770251 Bowman Sep 2017 B2
9770577 Li Sep 2017 B2
9775621 Tompkins et al. Oct 2017 B2
9775706 Peterson Oct 2017 B2
9775732 Khenansho Oct 2017 B2
9788800 Mayoras, Jr. Oct 2017 B2
9795391 Saatchi et al. Oct 2017 B2
9801980 Karino et al. Oct 2017 B2
9808599 Bowman Nov 2017 B2
9833252 Sepetka Dec 2017 B2
9833304 Horan et al. Dec 2017 B2
9833604 Lam Dec 2017 B2
9833625 Waldhauser et al. Dec 2017 B2
9901434 Hoffman Feb 2018 B2
9918720 Marchand et al. Mar 2018 B2
10016206 Yang Jul 2018 B1
10070878 Ma Sep 2018 B2
10098651 Marchand et al. Oct 2018 B2
10201360 Vale et al. Feb 2019 B2
10231751 Sos Mar 2019 B2
10292723 Brady et al. May 2019 B2
10299811 Brady et al. May 2019 B2
10363054 Vale et al. Jul 2019 B2
10376274 Farin et al. Aug 2019 B2
10390850 Vale et al. Aug 2019 B2
10524811 Marchand et al. Jan 2020 B2
10617435 Vale et al. Apr 2020 B2
10722257 Skillrud et al. Jul 2020 B2
20010001315 Bates et al. May 2001 A1
20010016755 Addis Aug 2001 A1
20010037141 Yee et al. Nov 2001 A1
20010041909 Tsugita et al. Nov 2001 A1
20010049554 Ruiz et al. Dec 2001 A1
20010051810 Dubrul et al. Dec 2001 A1
20020004667 Adams et al. Jan 2002 A1
20020016609 Wensel et al. Feb 2002 A1
20020022859 Hogendijk Feb 2002 A1
20020026211 Khosravi et al. Feb 2002 A1
20020042627 Brady et al. Apr 2002 A1
20020049468 Streeter et al. Apr 2002 A1
20020052620 Barbut May 2002 A1
20020058911 Gilson et al. May 2002 A1
20020068954 Foster Jun 2002 A1
20020072764 Sepetka et al. Jun 2002 A1
20020082558 Samson et al. Jun 2002 A1
20020091407 Zadno-Azizi et al. Jul 2002 A1
20020095171 Belef Jul 2002 A1
20020123765 Sepetka et al. Sep 2002 A1
20020138094 Borillo et al. Sep 2002 A1
20020143349 Gifford, III et al. Oct 2002 A1
20020143362 Macoviak et al. Oct 2002 A1
20020156455 Barbut Oct 2002 A1
20020161393 Demond et al. Oct 2002 A1
20020165576 Boyle et al. Nov 2002 A1
20020173819 Leeflang et al. Nov 2002 A1
20020183787 Wahr et al. Dec 2002 A1
20020188276 Evans et al. Dec 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20020193824 Boylan et al. Dec 2002 A1
20020198588 Armstrong et al. Dec 2002 A1
20030004536 Boylan et al. Jan 2003 A1
20030004538 Secrest et al. Jan 2003 A1
20030004540 Linder et al. Jan 2003 A1
20030004542 Wensel et al. Jan 2003 A1
20030009146 Muni et al. Jan 2003 A1
20030009191 Wensel et al. Jan 2003 A1
20030038447 Cantele Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030050663 Khachin et al. Mar 2003 A1
20030114879 Euteneuer et al. Jun 2003 A1
20030125798 Martin Jul 2003 A1
20030130682 Broome et al. Jul 2003 A1
20030144687 Brady et al. Jul 2003 A1
20030144688 Brady et al. Jul 2003 A1
20030153943 Michael et al. Aug 2003 A1
20030153944 Phung et al. Aug 2003 A1
20030163064 Vrba et al. Aug 2003 A1
20030163158 White Aug 2003 A1
20030171769 Barbut Sep 2003 A1
20030171771 Anderson et al. Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030195537 Dubrul et al. Oct 2003 A1
20030195554 Shen et al. Oct 2003 A1
20030199917 Knudson et al. Oct 2003 A1
20030204202 Palmer et al. Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030212430 Bose et al. Nov 2003 A1
20030236533 Wilson et al. Dec 2003 A1
20040064179 Linder et al. Apr 2004 A1
20040068288 Palmer et al. Apr 2004 A1
20040073243 Sepetka et al. Apr 2004 A1
20040079429 Miller et al. Apr 2004 A1
20040082962 Demarais et al. Apr 2004 A1
20040082967 Broome et al. Apr 2004 A1
20040088001 Bosma et al. May 2004 A1
20040093065 Yachia et al. May 2004 A1
20040098050 Foerster et al. May 2004 A1
20040133231 Maitland et al. Jul 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040138692 Phung et al. Jul 2004 A1
20040153117 Clubb et al. Aug 2004 A1
20040153118 Clubb et al. Aug 2004 A1
20040199201 Kellett et al. Oct 2004 A1
20040215318 Kwitkin Oct 2004 A1
20040220663 Rivelli Nov 2004 A1
20050033348 Sepetka et al. Feb 2005 A1
20050038447 Huffmaster Feb 2005 A1
20050038468 Panetta et al. Feb 2005 A1
20050043759 Chanduszko Feb 2005 A1
20050049619 Sepetka et al. Mar 2005 A1
20050049669 Jones et al. Mar 2005 A1
20050049670 Jones et al. Mar 2005 A1
20050055033 Leslie et al. Mar 2005 A1
20050055047 Greenhalgh Mar 2005 A1
20050059995 Sepetka et al. Mar 2005 A1
20050085849 Sepetka et al. Apr 2005 A1
20050090779 Osypka Apr 2005 A1
20050090857 Kusleika et al. Apr 2005 A1
20050125024 Sepetka et al. Jun 2005 A1
20050171566 Kanamaru Aug 2005 A1
20050192627 Whisenant et al. Sep 2005 A1
20050216030 Sepetka et al. Sep 2005 A1
20050216050 Sepetka et al. Sep 2005 A1
20050228417 Teitelbaum et al. Oct 2005 A1
20050251206 Maahs et al. Nov 2005 A1
20050251209 Saadat et al. Nov 2005 A1
20050267491 Kellett et al. Dec 2005 A1
20050273135 Chanduszko et al. Dec 2005 A1
20050283186 Berrada et al. Dec 2005 A1
20050288686 Sepetka et al. Dec 2005 A1
20060009798 Callister et al. Jan 2006 A1
20060009799 Kleshinski et al. Jan 2006 A1
20060020285 Niermann Jan 2006 A1
20060020286 Niermann Jan 2006 A1
20060030877 Martinez et al. Feb 2006 A1
20060041228 Vo et al. Feb 2006 A1
20060058836 Bose et al. Mar 2006 A1
20060058837 Bose et al. Mar 2006 A1
20060058838 Bose et al. Mar 2006 A1
20060064151 Guterman Mar 2006 A1
20060069424 Acosta et al. Mar 2006 A1
20060074477 Berthiaume et al. Apr 2006 A1
20060149313 Arguello et al. Jul 2006 A1
20060155305 Freudenthal et al. Jul 2006 A1
20060161187 Levine et al. Jul 2006 A1
20060195137 Sepetka et al. Aug 2006 A1
20060224177 Finitsis Oct 2006 A1
20060224179 Kucharczyk et al. Oct 2006 A1
20060229638 Abrams et al. Oct 2006 A1
20060235501 Igaki Oct 2006 A1
20060241677 Johnson et al. Oct 2006 A1
20060282111 Morsi Dec 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20060287701 Pal Dec 2006 A1
20060293706 Shimon Dec 2006 A1
20070010857 Sugimoto et al. Jan 2007 A1
20070032879 Levine et al. Feb 2007 A1
20070088382 Bei et al. Apr 2007 A1
20070088383 Pal et al. Apr 2007 A1
20070100348 Cauthen, III et al. May 2007 A1
20070118173 Magnuson et al. May 2007 A1
20070149997 Muller Jun 2007 A1
20070156170 Hancock et al. Jul 2007 A1
20070165170 Fukuda Jul 2007 A1
20070179527 Eskuri et al. Aug 2007 A1
20070191866 Palmer et al. Aug 2007 A1
20070198028 Miloslavski et al. Aug 2007 A1
20070198051 Clubb et al. Aug 2007 A1
20070198075 Levy Aug 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070208371 French et al. Sep 2007 A1
20070225749 Martin et al. Sep 2007 A1
20070233175 Zaver et al. Oct 2007 A1
20070244505 Gilson et al. Oct 2007 A1
20070270902 Slazas et al. Nov 2007 A1
20070288054 Tanaka et al. Dec 2007 A1
20080045881 Teitelbaum et al. Feb 2008 A1
20080077227 Ouellette et al. Mar 2008 A1
20080082107 Miller et al. Apr 2008 A1
20080086190 Ta Apr 2008 A1
20080091223 Pokorney et al. Apr 2008 A1
20080097386 Osypka Apr 2008 A1
20080109031 Sepetka et al. May 2008 A1
20080109032 Sepetka et al. May 2008 A1
20080119886 Greenhalgh et al. May 2008 A1
20080125798 Osborne et al. May 2008 A1
20080177296 Sepetka et al. Jul 2008 A1
20080178890 Townsend et al. Jul 2008 A1
20080183197 Sepetka et al. Jul 2008 A1
20080183198 Sepetka et al. Jul 2008 A1
20080183205 Sepetka et al. Jul 2008 A1
20080188876 Sepetka et al. Aug 2008 A1
20080188885 Sepetka et al. Aug 2008 A1
20080188887 Batiste Aug 2008 A1
20080200946 Braun et al. Aug 2008 A1
20080200947 Kusleika et al. Aug 2008 A1
20080215077 Sepetka et al. Sep 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20080228209 DeMello et al. Sep 2008 A1
20080234706 Sepetka et al. Sep 2008 A1
20080243170 Jenson et al. Oct 2008 A1
20080255596 Jenson et al. Oct 2008 A1
20080262410 Jenson et al. Oct 2008 A1
20080262528 Martin Oct 2008 A1
20080262532 Martin Oct 2008 A1
20080269871 Eli Oct 2008 A1
20080275488 Fleming Nov 2008 A1
20080275493 Farmiga Nov 2008 A1
20080281350 Sepetka Nov 2008 A1
20080312681 Ansel et al. Dec 2008 A1
20090005858 Young et al. Jan 2009 A1
20090024157 Anukhin Jan 2009 A1
20090030443 Buser et al. Jan 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090069828 Martin et al. Mar 2009 A1
20090076539 Valaie Mar 2009 A1
20090088793 Bagaoisan et al. Apr 2009 A1
20090088795 Cahill Apr 2009 A1
20090105722 Fulkerson et al. Apr 2009 A1
20090105737 Fulkerson et al. Apr 2009 A1
20090105747 Chanduszko et al. Apr 2009 A1
20090149881 Vale et al. Jun 2009 A1
20090163851 Holloway et al. Jun 2009 A1
20090177206 Lozier et al. Jul 2009 A1
20090182336 Brenzel et al. Jul 2009 A1
20090281610 Parker Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090292297 Ferrere Nov 2009 A1
20090292307 Razack Nov 2009 A1
20090299393 Martin et al. Dec 2009 A1
20090299403 Chanduszko et al. Dec 2009 A1
20090306702 Miloslavski et al. Dec 2009 A1
20090326636 Hashimoto et al. Dec 2009 A1
20100004607 Wilson et al. Jan 2010 A1
20100076482 Shu et al. Mar 2010 A1
20100087850 Razack Apr 2010 A1
20100087908 Hilaire et al. Apr 2010 A1
20100114017 Lenker et al. May 2010 A1
20100125326 Kalstad et al. May 2010 A1
20100125327 Agnew May 2010 A1
20100191272 Keating Jul 2010 A1
20100211094 Sargent, Jr. Aug 2010 A1
20100268264 Bonnette et al. Oct 2010 A1
20100268265 Krolik et al. Oct 2010 A1
20100274277 Eaton Oct 2010 A1
20100318178 Rapaport et al. Dec 2010 A1
20100324649 Mattsson Dec 2010 A1
20100331949 Habib Dec 2010 A1
20110009875 Grandfield et al. Jan 2011 A1
20110009940 Grandfield et al. Jan 2011 A1
20110009950 Grandfield et al. Jan 2011 A1
20110015718 Schreck Jan 2011 A1
20110022149 Cox et al. Jan 2011 A1
20110040319 Fulton, III Feb 2011 A1
20110054504 Porter Mar 2011 A1
20110054514 Arcand et al. Mar 2011 A1
20110054516 Keegan et al. Mar 2011 A1
20110060212 Slee et al. Mar 2011 A1
20110060359 Hannes et al. Mar 2011 A1
20110106137 Shimon May 2011 A1
20110125181 Brady et al. May 2011 A1
20110152920 Eckhouse et al. Jun 2011 A1
20110160763 Ferrera et al. Jun 2011 A1
20110166586 Sepetka et al. Jul 2011 A1
20110184456 Grandfield et al. Jul 2011 A1
20110196414 Porter Aug 2011 A1
20110202088 Eckhouse et al. Aug 2011 A1
20110208233 McGuckin, Jr. et al. Aug 2011 A1
20110213297 Aklog et al. Sep 2011 A1
20110213393 Aklog et al. Sep 2011 A1
20110213403 Aboytes Sep 2011 A1
20110224707 Miloslavski et al. Sep 2011 A1
20110276120 Gilson et al. Nov 2011 A1
20110319917 Ferrera et al. Dec 2011 A1
20120022572 Braun Jan 2012 A1
20120041449 Eckhouse et al. Feb 2012 A1
20120041474 Eckhouse et al. Feb 2012 A1
20120059356 di Palma et al. Mar 2012 A1
20120065660 Ferrera et al. Mar 2012 A1
20120083823 Shrivastava et al. Apr 2012 A1
20120083868 Shrivastava et al. Apr 2012 A1
20120089216 Rapaport et al. Apr 2012 A1
20120101510 Lenker et al. Apr 2012 A1
20120123466 Porter et al. May 2012 A1
20120143237 Cam et al. Jun 2012 A1
20120150147 Leynov et al. Jun 2012 A1
20120165858 Eckhouse et al. Jun 2012 A1
20120165859 Eckhouse et al. Jun 2012 A1
20120209312 Aggerholm et al. Aug 2012 A1
20120215250 Grandfield et al. Aug 2012 A1
20120277788 Cattaneo Nov 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120296362 Cam et al. Nov 2012 A1
20120316600 Ferrera et al. Dec 2012 A1
20120330350 Jones et al. Dec 2012 A1
20130030460 Marks et al. Jan 2013 A1
20130030461 Marks et al. Jan 2013 A1
20130046330 McIntosh et al. Feb 2013 A1
20130046333 Jones et al. Feb 2013 A1
20130046334 Jones et al. Feb 2013 A1
20130116774 Strauss et al. May 2013 A1
20130131614 Hassan et al. May 2013 A1
20130144311 Fung et al. Jun 2013 A1
20130144326 Brady et al. Jun 2013 A1
20130158592 Porter Jun 2013 A1
20130184739 Brady et al. Jul 2013 A1
20130197567 Brady et al. Aug 2013 A1
20130226146 Tekulve Aug 2013 A1
20130268050 Wilson et al. Oct 2013 A1
20130281788 Garrison Oct 2013 A1
20130325051 Martin et al. Dec 2013 A1
20130325055 Eckhouse et al. Dec 2013 A1
20130325056 Eckhouse et al. Dec 2013 A1
20130345739 Brady Dec 2013 A1
20140005712 Martin Jan 2014 A1
20140005713 Bowman Jan 2014 A1
20140046359 Bowman et al. Feb 2014 A1
20140121672 Folk May 2014 A1
20140128905 Molaei May 2014 A1
20140134654 Rudel et al. May 2014 A1
20140135812 Divino et al. May 2014 A1
20140142598 Fulton, III May 2014 A1
20140180122 Stigall et al. Jun 2014 A1
20140180377 Bose et al. Jun 2014 A1
20140180397 Gerberding et al. Jun 2014 A1
20140194911 Johnson et al. Jul 2014 A1
20140194919 Losordo et al. Jul 2014 A1
20140200607 Sepetka et al. Jul 2014 A1
20140200608 Brady et al. Jul 2014 A1
20140236220 Inoue Aug 2014 A1
20140243881 Lees et al. Aug 2014 A1
20140257362 Eidenschink Sep 2014 A1
20140276922 McLain et al. Sep 2014 A1
20140277079 Vale et al. Sep 2014 A1
20140303667 Cox et al. Oct 2014 A1
20140309657 Ben-Ami Oct 2014 A1
20140309673 Dacuycuy et al. Oct 2014 A1
20140330302 Fekulve et al. Nov 2014 A1
20140343585 Ferrera et al. Nov 2014 A1
20140371769 Vale et al. Dec 2014 A1
20140371779 Vale et al. Dec 2014 A1
20140371780 Vale et al. Dec 2014 A1
20140379023 Brady et al. Dec 2014 A1
20150018859 Quick et al. Jan 2015 A1
20150018860 Quick et al. Jan 2015 A1
20150032144 Holloway Jan 2015 A1
20150080937 Davidson Mar 2015 A1
20150112376 Molaei Apr 2015 A1
20150133990 Davidson May 2015 A1
20150150672 Ma Jun 2015 A1
20150164523 Brady et al. Jun 2015 A1
20150224133 Ohri et al. Aug 2015 A1
20150250497 Marks et al. Sep 2015 A1
20150257775 Gilvarry et al. Sep 2015 A1
20150272716 Pinchuk et al. Oct 2015 A1
20150297252 Miloslavski et al. Oct 2015 A1
20150313617 Grandfield et al. Nov 2015 A1
20150320431 Ulm Nov 2015 A1
20150352325 Quick Dec 2015 A1
20150359547 Vale et al. Dec 2015 A1
20150366650 Zi et al. Dec 2015 A1
20150374391 Quick et al. Dec 2015 A1
20150374393 Brady et al. Dec 2015 A1
20150374479 Vale Dec 2015 A1
20160015402 Brady et al. Jan 2016 A1
20160022296 Brady et al. Jan 2016 A1
20160045298 Thinnes, Jr. et al. Feb 2016 A1
20160066921 Seifert et al. Mar 2016 A1
20160100928 Lees et al. Apr 2016 A1
20160106448 Brady et al. Apr 2016 A1
20160106449 Brady et al. Apr 2016 A1
20160113663 Brady et al. Apr 2016 A1
20160113664 Brady et al. Apr 2016 A1
20160113665 Brady et al. Apr 2016 A1
20160120558 Brady et al. May 2016 A1
20160143653 Vale et al. May 2016 A1
20160192953 Brady et al. Jul 2016 A1
20160192954 Brady et al. Jul 2016 A1
20160192955 Brady et al. Jul 2016 A1
20160192956 Brady et al. Jul 2016 A1
20160256180 Vale et al. Sep 2016 A1
20160303381 Pierce et al. Oct 2016 A1
20160317168 Brady et al. Nov 2016 A1
20170007264 Cruise et al. Jan 2017 A1
20170007265 Guo et al. Jan 2017 A1
20170020542 Martin et al. Jan 2017 A1
20170020670 Murray et al. Jan 2017 A1
20170020700 Bienvenu Jan 2017 A1
20170027640 Kunis et al. Feb 2017 A1
20170027692 Bonhoeffer Feb 2017 A1
20170027725 Argentine Feb 2017 A1
20170035436 Morita Feb 2017 A1
20170035567 Duffy Feb 2017 A1
20170042548 Lam Feb 2017 A1
20170049596 Schabert Feb 2017 A1
20170056061 Ogle et al. Mar 2017 A1
20170071614 Vale et al. Mar 2017 A1
20170071737 Kelley Mar 2017 A1
20170072452 Monetti et al. Mar 2017 A1
20170079671 Morero Mar 2017 A1
20170079680 Bowman Mar 2017 A1
20170079766 Wang Mar 2017 A1
20170079767 Leon-Yip Mar 2017 A1
20170079812 Lam et al. Mar 2017 A1
20170079817 Sepetka Mar 2017 A1
20170079819 Pung et al. Mar 2017 A1
20170079820 Lam et al. Mar 2017 A1
20170086851 Wallace Mar 2017 A1
20170086862 Vale et al. Mar 2017 A1
20170086863 Brady et al. Mar 2017 A1
20170086996 Peterson et al. Mar 2017 A1
20170095259 Tompkins et al. Apr 2017 A1
20170100126 Bowman et al. Apr 2017 A1
20170100141 Morero et al. Apr 2017 A1
20170100143 Granfield Apr 2017 A1
20170100183 Iaizzo Apr 2017 A1
20170105743 Vale et al. Apr 2017 A1
20170112515 Brady et al. Apr 2017 A1
20170112647 Sachar et al. Apr 2017 A1
20170113023 Steingisser et al. Apr 2017 A1
20170119409 Ma May 2017 A1
20170143465 Ulm, III May 2017 A1
20170147765 Mehta May 2017 A1
20170150979 John Jun 2017 A1
20170151032 Loisel Jun 2017 A1
20170165062 Rothstein Jun 2017 A1
20170165065 Rothstein Jun 2017 A1
20170165454 Tuohy Jun 2017 A1
20170172581 Bose et al. Jun 2017 A1
20170172766 Vong et al. Jun 2017 A1
20170172772 Khenansho Jun 2017 A1
20170189033 Sepetka et al. Jul 2017 A1
20170189035 Porter Jul 2017 A1
20170215902 Leynov et al. Aug 2017 A1
20170216484 Cruise et al. Aug 2017 A1
20170224350 Shimizu et al. Aug 2017 A1
20170224355 Bowman et al. Aug 2017 A1
20170224467 Piccagli et al. Aug 2017 A1
20170224511 Dwork et al. Aug 2017 A1
20170224953 Tran et al. Aug 2017 A1
20170231749 Perkins et al. Aug 2017 A1
20170252064 Staunton Sep 2017 A1
20170265983 Lam et al. Sep 2017 A1
20170281192 Tieu et al. Oct 2017 A1
20170281331 Perkins et al. Oct 2017 A1
20170281344 Costello Oct 2017 A1
20170281909 Northrop et al. Oct 2017 A1
20170281912 Melder Oct 2017 A1
20170290593 Cruise et al. Oct 2017 A1
20170290654 Sethna Oct 2017 A1
20170296324 Argentine Oct 2017 A1
20170296325 Marrocco et al. Oct 2017 A1
20170303939 Greenhalgh Oct 2017 A1
20170303942 Greenhalgh et al. Oct 2017 A1
20170303947 Greenhalgh Oct 2017 A1
20170303948 Wallace et al. Oct 2017 A1
20170304041 Argentine Oct 2017 A1
20170304097 Corwin et al. Oct 2017 A1
20170304595 Nagasrinivasa Oct 2017 A1
20170312109 Le Nov 2017 A1
20170312484 Shipley et al. Nov 2017 A1
20170316561 Helm et al. Nov 2017 A1
20170319826 Bowman Nov 2017 A1
20170333228 Orth et al. Nov 2017 A1
20170333236 Greenan Nov 2017 A1
20170333678 Bowman Nov 2017 A1
20170340383 Bloom et al. Nov 2017 A1
20170348014 Wallace Dec 2017 A1
20170348514 Guyon et al. Dec 2017 A1
20180263650 Iwanami et al. Sep 2018 A1
20180325537 Shamay et al. Nov 2018 A1
20180326024 Prochazka et al. Nov 2018 A1
20180344338 Brady et al. Dec 2018 A1
20190000492 Casey et al. Jan 2019 A1
20190015061 Liebeskind et al. Jan 2019 A1
20190167284 Friedman et al. Jun 2019 A1
20190239907 Brady et al. Aug 2019 A1
20190292273 Hanotin et al. Sep 2019 A1
20190374239 Martin et al. Dec 2019 A1
20190380723 Grandfield et al. Dec 2019 A1
20190388097 Girdhar et al. Dec 2019 A1
20200009150 Chamorro Sanchez Jan 2020 A1
20200100804 Casey et al. Apr 2020 A1
20200297364 Choe et al. Sep 2020 A1
Foreign Referenced Citations (102)
Number Date Country
2557083 Jun 2003 CN
101172051 May 2008 CN
102307613 Jan 2012 CN
102596098 Jul 2012 CN
103764049 Apr 2014 CN
104042304 Sep 2014 CN
105208950 Dec 2015 CN
105662532 Jun 2016 CN
205359559 Jul 2016 CN
107530090 Jan 2018 CN
208582467 Mar 2019 CN
202009001951 Mar 2010 DE
102009056450 Jun 2011 DE
102010010849 Sep 2011 DE
102010014778 Oct 2011 DE
102010024085 Dec 2011 DE
102011014586 Sep 2012 DE
2301450 Mar 2011 EP
1153581 Nov 2011 EP
2438891 Apr 2012 EP
2628455 Aug 2013 EP
3156004 Apr 2017 EP
2427554 Jan 2007 GB
2494820 Mar 2013 GB
09-19438 Jan 1997 JP
2014-511223 May 2014 JP
2014-525796 Oct 2014 JP
2016-513505 May 2016 JP
2019-526365 Sep 2019 JP
WO 9424926 Nov 1994 WO
WO 9727808 Aug 1997 WO
WO 9738631 Oct 1997 WO
WO 9920335 Apr 1999 WO
WO 9956801 Nov 1999 WO
WO 9960933 Dec 1999 WO
WO 0121077 Mar 2001 WO
WO 0202162 Jan 2002 WO
WO 0211627 Feb 2002 WO
WO 0243616 Jun 2002 WO
WO 02070061 Sep 2002 WO
WO 02094111 Nov 2002 WO
WO 03002006 Jan 2003 WO
WO 03030751 Apr 2003 WO
WO 03051448 Jun 2003 WO
WO 2004028571 Apr 2004 WO
WO 2004056275 Jul 2004 WO
WO 2005000130 Jan 2005 WO
WO 2005027779 Mar 2005 WO
WO 2006021407 Mar 2006 WO
WO 2006031410 Mar 2006 WO
WO 2006107641 Oct 2006 WO
WO 2006135823 Dec 2006 WO
WO 2007054307 May 2007 WO
WO 2007068424 Jun 2007 WO
WO 2008034615 Mar 2008 WO
WO 2008051431 May 2008 WO
WO 2008131116 Oct 2008 WO
WO 2008135823 Nov 2008 WO
WO 2009031338 Mar 2009 WO
WO 2009076482 Jun 2009 WO
WO 2009086482 Jul 2009 WO
WO 2009105710 Aug 2009 WO
WO 2010010545 Jan 2010 WO
WO 2010046897 Apr 2010 WO
WO 2010075565 Jul 2010 WO
WO 2010102307 Sep 2010 WO
WO 2010146581 Dec 2010 WO
WO 2011013556 Feb 2011 WO
WO 2011066961 Jun 2011 WO
WO 2011082319 Jul 2011 WO
WO 2011095352 Aug 2011 WO
WO 2011106426 Sep 2011 WO
WO 2011110316 Sep 2011 WO
WO 2011135556 Nov 2011 WO
WO 2012052982 Apr 2012 WO
WO 2012064726 May 2012 WO
WO 2012081020 Jun 2012 WO
WO 2012110619 Aug 2012 WO
WO 2012120490 Sep 2012 WO
WO 2012156924 Nov 2012 WO
WO 2013016435 Jan 2013 WO
WO 2013072777 May 2013 WO
WO 2013105099 Jul 2013 WO
WO 2013109756 Jul 2013 WO
WO 2013187927 Dec 2013 WO
WO 2014047650 Mar 2014 WO
WO 2014081892 May 2014 WO
WO 2014139845 Sep 2014 WO
WO 2014169266 Oct 2014 WO
WO 2014178198 Nov 2014 WO
WO 2015061365 Apr 2015 WO
WO 2015103547 Jul 2015 WO
WO 2015134625 Sep 2015 WO
WO 2015179324 Nov 2015 WO
WO 2015189354 Dec 2015 WO
WO 2016010995 Jan 2016 WO
WO 2016089451 Jun 2016 WO
WO 2017089424 Jun 2017 WO
WO 2017103686 Jun 2017 WO
WO 2017161204 Sep 2017 WO
WO 2020039082 Feb 2020 WO
WO 2021113302 Jun 2021 WO
Non-Patent Literature Citations (1)
Entry
US 6,348,062 B1, 02/2002, Hopkins et al. (withdrawn)
Related Publications (1)
Number Date Country
20210161544 A1 Jun 2021 US